Terms: = Uterine cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
5 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
[TBL] [Abstract] [Full Text] [Related]
3. Identification of an immune signature to predict poor clinical outcome in cervical cancer.
Yan W; Jin H; Zhang X; Long S; Xia Q; Meng D; Ding B; Li D; Ma J; Cao J; Wang S
Epigenomics; 2021 Jun; 13(11):891-907. PubMed ID: 33955785
[No Abstract] [Full Text] [Related]
4. Microsatellite instability status differentially associates with intratumoral immune microenvironment in human cancers.
Zhang P; Liu M; Cui Y; Zheng P; Liu Y
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32823273
[TBL] [Abstract] [Full Text] [Related]
5. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
Liang Y; Yu M; Zhou C; Zhu X
Diagn Pathol; 2020 Jun; 15(1):67. PubMed ID: 32493336
[TBL] [Abstract] [Full Text] [Related]
